108 results on '"Richardson, D.L."'
Search Results
2. Controls on residence time and exchange in a system of shallow coastal bays
3. 3P NaPi2b expression in high grade serous ovarian cancer: Results from combined data sets
4. 691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
5. 732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
6. 719MO A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer
7. 439TiP AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors
8. VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
9. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
10. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
11. 728P A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer
12. 961MO Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers
13. 921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
14. Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab
15. A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation
16. A phase IB trial of paclitaxel and carboplatin + galunisertib in patients with uterine and ovarian carcinosarcoma
17. 833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
18. 836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
19. 839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer
20. A simplified variation of parameters approach to Euler's equations
21. Modification of the Richardson-Panovsky methods for precise integration of satellite orbits
22. Provider perspective on medical marijuana in oncology
23. Impact of financial assistance programs on time to completion of therapy in women receiving chemoradiation for cervical cancer
24. Early-stage endometrial cancer with lymphovascular space invasion: Chemotherapy improves progression free survival and reduces distant metastases
25. Risk of Occult Endometrial Cancer during Hysterectomy for Benign Indications
26. Detection of Chronic Hepatitis B in Gynecologic Oncology Patients Undergoing Systemic Chemotherapy
27. GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer
28. Patient reported clinical outcomes and personal perspectives after risk reducing surgery
29. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study
30. 24 - Risk of Occult Endometrial Cancer during Hysterectomy for Benign Indications
31. INTERDISCIPLINARY APPROACH TO THE STUDY OF BEHAVIOR IN RELATED MICE TYPES
32. Factors associated with clinical trial screening failures in gynecologic oncology
33. Determination of the angular velocity vector in orthogonal curvilinear coordinate systems
34. Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors
35. Outcomes of third line chemotherapy for recurrent and persistent cervical cancer
36. Integrated approach to assessing mine-related impacts on the sustainable management of water resources: case study: Three Mile Creek, Collinsville (Northern Bowen Basin, Queensland).
37. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study
38. Ultrasound scan-guided core sampling for diagnosis versus freehand FNAC of the thyroid gland
39. Factors associated with clinical trial screening failures in gynecologic oncology
40. Upper GI 10
41. On the in-plane control of spacecraft relative motion
42. Treatment of right hepatic artery injury by percutaneous embolisation
43. Progression of an inductive signal activates sporulation in Dictyostelium discoideum
44. Ground-water concerns for the Eastern Shore, Virginia
45. Synechocystis PCC6803: a euryhaline cyanobacterium.
46. Combination Gemcitabine and Cisplatin for Recurrent Ovarian Cancer
47. Self-expanding metal stents in the palliation of small bowel stenosis secondary to recurrent gastric cancer
48. A family of implicit Chebyshev methods for the numerical integration of second-order differential equations
49. SynechocystisPCC6803: a euryhaline cyanobacterium
50. Prospective study of routine contrast radiology following total gastrectomy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.